Alcidion Expands Partnership with NextGate to UK Market

Alcidion LtdSmart health tech provider Alcidion Group Limited (ASX:ALC) has announced an expansion of its reseller agreement with NextGate to include the UK and Ireland.

In 2018, MKM Health (which was acquired by Alcidion in 2018) signed an agreement to resell NextGate's market leading Enterprise Master Patient Index (EMPI) and Provider Registry solutions in Australia and New Zealand. Following a successful two-year relationship, this agreement has now been extended to also include the UK and Ireland.

NextGate is the global leader in healthcare enterprise identification, helping healthcare organisations overcome the clinical, operational and financial challenges that result from duplicate records and disparate data.

Alcidion's reseller agreement with NextGate has resulted in two significant state-wide contracts in Australia. The Queensland Health Referral Service Directory based on the Provider Index was delivered by Alcidion working closely with NextGate. For the Victorian Department of Health and Human Services Unique Patient Identification program, Alcidion supported NextGate in delivery of its EMPI capability.

The expansion of the agreement to the UK and Ireland will further strengthen Alcidion's ability to support NHS trusts, health boards and region wide integrated care systems. The news follows the Alcidion's formal launch this summer of its Miya Precision product as the first smart clinical asset for the NHS.

Lynette Ousby, UK General Manager of Alcidion, said: "With the current focus in the NHS on consolidating clinical systems across regions, the ability to include the offering of NextGate solutions to complement our Miya Precision capability, establishes a true enterprise approach to healthcare delivery."

Alcidion's Miya Precision presents the NHS with an opportunity to move beyond static electronic records to technology that engages healthcare professionals. Early adopters are using the platform to orchestrate information across disparate systems using modern technology from Alcidion based on the FHIR standard and to establish smart clinical engagement supported by tailored clinical decision support.

With the ability to allow NHS organisations to use data to automate routine tasks, care plans and pathways, Miya Precision is being seen as a way to realise more value from electronic patient record investments and to provide a technology orchestration layer in trusts and for entire regions.

The addition of the NextGate Patient and Provider Registries, which are built on the MatchMetrix® master identity platform, will extend that capability to effectively manage identity for both patients and healthcare providers.

"We are delighted to expand our partnership with Alcidion to facilitate a modernised NHS infrastructure where patients are accurately identified and consistently matched to their health and social care data," said Andy Aroditis, CEO of NextGate. "Together, Alcidion and NextGate are delivering innovative interoperable solutions that maximise the quality, efficiency and coordination of care."

Alcidion Managing Director, Kate Quirke commented: "I am delighted that we can now expand our success implementing the NextGate solution in Australia to the UK. The combination of our service delivery and domain expertise with the powerful capabilities of MatchMetrix creates a compelling opportunity for the health sector to establish first class identity management."

About NextGate

With over 200 customers in six countries, NextGate is the global leader in healthcare enterprise identification. Committed to helping organizations overcome the clinical, operational and financial challenges that result from duplicate records and disparate data, our full suite of identity matching solutions connects the entire healthcare ecosystem to drive critical improvements in quality, efficiency and safety. NextGate’s market leading EMPI currently manages 300 million lives and is deployed by the nation’s most successful healthcare systems and health information exchanges.

About Alcidion

Alcidion (ASX:ALC) has a simple purpose: to transform healthcare with smart, intuitive technology solutions that meet the needs of hospital and allied healthcare, worldwide. It offers a complementary set of software products and services that create a unique offering in the global healthcare market; solutions that support interoperability, allow communication and task management, and deliver clinical decision support at the point of care to improve patient outcomes. In 2017 Alcidion acquired Oncall System and its Smartpage clinical communication system. In 2018 it acquired the Patientrack bedside patient monitoring software and MKM Health, an IT solutions and services provider. These offerings now operate under the Alcidion brand. With over 25 years of combined healthcare experience, Alcidion brings together the very best in technology and market knowledge to deliver solutions that make healthcare better for everyone.

Most Popular Now

Stepping Hill Hospital Announced as SPAR…

Stepping Hill Hospital, part of Stockport NHS Foundation Trust, has replaced its bedside units with state-of-the art devices running a full range of information, engagement, communications and productivity apps, to...

DMEA 2025: Digital Health Worldwide in B…

8 - 10 April 2025, Berlin, Germany. From the AI Act, to the potential of the European Health Data Space, to the power of patient data in Scandinavia - DMEA 2025...

New System for the Early Detection of Au…

A team from the Human-Tech Institute-Universitat Politècnica de València has developed a new system for the early detection of Autism Spectrum Disorder (ASD) using virtual reality and artificial intelligence. The...

Is AI in Medicine Playing Fair?

As artificial intelligence (AI) rapidly integrates into health care, a new study by researchers at the Icahn School of Medicine at Mount Sinai reveals that all generative AI models may...

Generative AI's Diagnostic Capabili…

The use of generative AI for diagnostics has attracted attention in the medical field and many research papers have been published on this topic. However, because the evaluation criteria were...

Diagnoses and Treatment Recommendations …

A new study led by Prof. Dan Zeltzer, a digital health expert from the Berglas School of Economics at Tel Aviv University, compared the quality of diagnostic and treatment recommendations...

AI Tool can Track Effectiveness of Multi…

A new artificial intelligence (AI) tool that can help interpret and assess how well treatments are working for patients with multiple sclerosis (MS) has been developed by UCL researchers. AI uses...

Surrey and Sussex Healthcare NHS Trust g…

Surrey and Sussex Healthcare NHS Trust has marked an important milestone in connecting busy radiologists across large parts of South East England, following the successful go live of Sectra's enterprise...

DMEA 2025 Ends with Record Attendance an…

8 - 10 April 2025, Berlin, Germany. DMEA 2025 came to a successful close with record attendance and an impressive program. 20,500 participants attended Europe's leading digital health event over the...

Dr Jason Broch Joins the Highland Market…

The Highland Marketing advisory board has welcomed a new member - Dr Jason Broch, a GP and director with a strong track record in the NHS and IT-enabled transformation. Dr Broch...

AI-Driven Smart Devices to Transform Hea…

AI-powered, internet-connected medical devices have the potential to revolutionise healthcare by enabling early disease detection, real-time patient monitoring, and personalised treatments, a new study suggests. They are already saving lives...

Multi-Resistance in Bacteria Predicted b…

An AI model trained on large amounts of genetic data can predict whether bacteria will become antibiotic-resistant. The new study shows that antibiotic resistance is more easily transmitted between genetically...